Eagle Pharmaceuticals, inc. (EGRX)

[Double_Bagel]

Teva reports Q2 EPS $1.25, consensus $1.20

Reports Q2 revenue $5.0B, consensus $4.87B.

Reports:
-- Copaxone revenue up 8% to $1.14B
-- Treanda and Bendeka revenue up 16% to $207M (from 179 million)

Teva's Investor Relations

Note: That is a huge jump from the previous quarter which was 155 million. So, Qtr-by-qtr increase from 155 million to 207 million. (33%). The first qtr of 2015 had sales of 157 million.

Can anybody figure out what is the royalty owed to EGRX for the quarter?